-
Johnson & Johnson NEW YORK STOCK EXCHANGE INC.:JNJ Johnson & Johnson believes good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, Johnson & Johnson has aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, Johnson & Johnson is committed to using its reach and size for good. Johnson & Johnson strives to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. Johnson & Johnson is blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.
Location: 1 Johnson And Johnson Plz, New Jersey, 08933-0001, US | Website: www.jnj.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
384.4B
Cash
20.3B
Avg Qtr Burn
N/A
Short % of Float
0.75%
Insider Ownership
0.09%
Institutional Own.
72.92%
Qtr Updated
09/29/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date | |
---|---|---|---|
TREMFYA (guselkumab) Details Crohns disease | No event data in pipeline | | |
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Details Multiple myeloma | Approved Update | ||
Approved Update | |||
AKEEGA (niraparib/abiraterone) Details Cancer, Castration-resistant prostate cancer | Approved Quarterly sales | ||
CARVYKTI (ciltacabtagene autoleucel) Details Multiple myeloma, Cancer | Approved Quarterly sales | ||
RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) Details Cancer, Non-small cell lung carcinoma | Approved Quarterly sales | ||
DARZALEX (daratumumab) Details Cancer, Multiple myeloma | Approved Quarterly sales | ||
OPSUMIT (macitentan) Details Pulmonary arterial hypertension | Approved Quarterly sales | ||
TECVAYLI® (teclistamab-cqyv) Details Multiple myeloma, Cancer | Approved Quarterly sales | ||
TREMFYA (guselkumab) Details Ulcerative colitis | Approved Quarterly sales | ||
UPTRAVI (selexipag) Details Pulmonary arterial hypertension | Approved Quarterly sales | ||
BALVERSA (erdafitinib) Details Cancer, Urothelial cancer | Approved Quarterly sales | ||
SPRAVATO (esketamine) Details Treatment Resistant Depression | Approved Quarterly sales | ||
TREMFYA (guselkumab) Details Psoriasis | Approved Quarterly sales | ||
IMBRUVICA (ibrutinib) Details Chronic lymphocytic leukemia | Approved Quarterly sales | ||
TALVEY (talquetamab) Details Multiple myeloma, Cancer | Approved Quarterly sales | ||
Nipocalimab Details Myasthenia gravis, Autoimmune disease | BLA Acceptance for review | ||
BLA Acceptance for review | |||
OPSUMIT (macitentan) w/tadalafil FDC Details Pulmonary arterial hypertension | NDA Submission | ||
VARIPULSE™ Details Atrial fibrillation | Phase 3 Update | ||
RYBREVANT (amivantamab) + Chemotherapy Details Cancer, Non-small cell lung carcinoma | Phase 3 Update | ||
TREMFYA (guselkumab) Details Crohns disease | Phase 3 Update | ||
TREMFYA (guselkumab) Details Psoriasis | Phase 3 Update | ||
Nipocalimab Details Myasthenia gravis, Autoimmune disease | Phase 2/3 Update | ||
TAR-200 (RIS/gemcitabine plus cetrelimab) Details Cancer, Non-muscle invasive bladder cancer | Phase 2b Update | ||
TAR-200 (RIS/gemcitabine plus cetrelimab) Details Cancer, Muscle-invasive bladder cancer | Phase 2 Data readout | ||
Nipocalimab Details Autoimmune disease, Sjögren-Larsson Syndrome | Phase 2 Data readout | ||
RYBREVANT ( SC amivantamab) + lazertinib) Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | ||
BALVERSA (erdafitinib) Details Solid tumor/s | Phase 2 Update | ||
nipocalimab Details Warm autoimmune hemolytic anemia | Phase 2 Update | ||
RYBREVANT (intravenous) Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | ||
NM26 Details Atopic dermatitis, Skin disease/disorder | Phase 2 Initiation | ||
nipocalimab Details Rheumatoid arthritis | Phase 2a Data readout | ||
RYBREVANT (amivantamab) + Chemotherapy Details Cancer, Metastatic colorectal cancer | Phase 1/2 Update | ||
TAR-210 (RIS/erdafitinib) Details Cancer, Non-muscle invasive bladder cancer | Phase 1 Data readout | ||
IMBRUVICA (ibrutinib) Details Lymphoma, Mantle cell lymphoma, Marginal zone lymphoma | Failed Discontinued |